VRXA · ISSUER CIK 2079109
Veraxa Biotech AG - Post de-SPAC
Between Aug 1, 2026 and Oct 29, 2026, 4 Veraxa Biotech AG - Post de-SPAC insiders reported $125K of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was Baumann Oliver Rolf (Director), with $75K.
↗4 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$125KInsider buying
$0.00Insider selling
+$125KNet open-market
Oct 29, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 29, 202616:52 | Oct 28, 2026from Oct 27, 2026 | VRXA | Director | P · Buy | $1.00 | +10,000 | 10,000 | New | +$10K | -49.8% | +13.2% |
| Oct 21, 202616:10 | Oct 20, 2026 | VRXA | Director | P · Buy | $1.09 | +30,000 | 37,932 | +378% | +$33K | -46.8% | +3.7% |
| Aug 31, 202616:10 | Aug 27, 2026 | VRXA | Director | P · Buy | $1.50 | +50,000 | 5,773,618 | +1% | +$75K | -94.0% | -24.7% |
| Aug 31, 202616:10 | Aug 27, 2026 | VRXA | Chief Executive Officer, Director | P · Buy | $1.53 | +5,000 | 5,000 | New | +$8K | -93.8% | -26.1% |